A case–control study evaluated the effects of tadalafil and sildenafil on the thrombotic markers in patients with congenital heart diseases and showed that PDE5 inhibitors reduced thrombomodulin, P-selectin, and tissue plasminogen activator (tPA) [107, 108]. Here, PLAT is linked to congenital heart disease.